Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases

1. A compound of Formula I:

or a pharmaceutically acceptable salt or solvate thereof,

wherein:

X 1 , X 2 , X 3 , X 4 , X 5 are hydrogen and X 3 is n-propyl, n-butyl, nitro or dialkylamino, or

X 2 , X 3 , X 4 , X 5 are hydrogen and X 1 is fluoro, iodo, C1-C4-alkyl, C1-C2-haloalkyl, cyano, nitro, or dialkylamino, or

X 1 , X 3 , X 4 , X 5 are hydrogen and X 2 is C1-C4-aklyl, C1-C2-haloalkyl, cyano, nitro, or

X 3 , X 4 , and X 5 are hydrogen and X 1 and X 2 are independently selected from the group consisting of chloro, C1-C4-alkyl, C1-C2-haloalkyl, cyano, nitro, and dialkylamino, or

X 2 , X 4 , and X 5 are hydrogen and X 1 and X 3 are independently selected from the group consisting of chloro, C1-C4-alkyl, C1C2-haloalkyl, cyano, nitro, and dialkylamino, or

X 1 , X 4 , and X 5 are hydrogen and X 2 and X 3 are independently selected from the group consisting of chloro, C1-C4-alkyl, C1-C2-haloalkyl, C1-C2-alkoxy, cyano, nitro, and dialkylamino, or

X 1 , X 3 , and X 5 are hydrogen and X 2 and X 4 are independently selected from the group consisting of chloro, C1-C4-alkyl, C1-C2-haloalkyl, C1-C2-alkoxy, cyano, nitro, and dialkylamino;

L is —C(O)NH—;

n is 0, or 1;

m is 1, 2, 3, 4 or 5;

R 1 is methyl, and

R 2 is 5- or 6-membered arylalkyl, 5- or 6-membered cycloalkylalkyl, wherein the cyclic moiety of said arylalkyl or cycloalkylalkyl is optionally substituted by one or more substituents independently selected from halogen.

2. The compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein n is 0.

3. The compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is 5- or 6-membered aryl-C1-C2-alkyl.

4. The compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein m is 2, 3 or 4.

5. The compound according to claim 1 , having Formula II

or a pharmaceutically acceptable salt or solvate thereof,

wherein:

X 3 , m, R 1 , and R 2 are as defined in claim 1 , with the proviso that X 3 is not hydrogen.

6. The compound according to claim 1 , having Formula III

or a pharmaceutically acceptable salt or solvate thereof,

wherein:

X 1 , X 2 , X 3 , X 4 , X 5 , L, n and m are as defined in claim 1 ;

p is 1 or 2;

X 6 , X 7 , X 8 , X 9 , X 10 are independently selected from H and halogen.

7. The compound according to claim 1 , having Formula IV

8. The compound according to claim 1 selected from the group consisting of:

N-[3-(benzylmethylamino)propyl]-4-propylbenzamide;

N-[3-(benzylmethylamino)propyl]-4-butylbenzamide;

N-[3-(benzylmethylamino)propyl]-2,3-dichlorobenzamide;

N-[3-(benzylmethylamino)propyl]-2,4-dichlorobenzamide;

N-[3-(benzylmethylamino)propyl]-3,4-dichlorobenzamide;

N-[3-(benzylmethylamino)propyl]-3,5-dichlorobenzamide;

N-[3-(benzylmethylamino)propyl]-4-nitrobenzamide;

N-(2-(benzyl(methyl)amino)ethyl)-2,4-dichlorobenzamide; and

N-(2-(benzyl(methyl)amino)ethyl)-4-nitrobenzamide.

9. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant.